Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Matthew J, Monberg"'
Publikováno v:
Future Oncology.
Aim: Real-world data on treatment patterns and outcomes of advanced ovarian cancer (OC) patients since bevacizumab approval in first-line (1L) OC treatment were assessed. Materials & methods: In this descriptive retrospective study using the ConcertA
Autor:
Dominic Muston, Robert Hettle, Su Zhang, Wei Gao, Kimmie K. McLaurin, Matthew J. Monberg, Elyse Swallow, Kathleen N. Moore, James Signorovitch, Iden Kalemaj
Publikováno v:
Gynecologic Oncology. 159:491-497
Objective This study evaluated the cost-effectiveness of olaparib monotherapy in the first-line maintenance setting vs. surveillance in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation from a US third-party payer perspective.
Publikováno v:
E-Posters.
Autor:
Elizabeth A. Szamreta, Mansi Modi, Ramu Periyasamy, Bhavani Yamsani, Sumedha Kulkarni, Matthew J. Monberg
Publikováno v:
Journal of Clinical Oncology. 40:e17533-e17533
e17533 Background: Real-world evidence (RWE) studies complement clinical trials (CT) and address a variety of issues, such as adherence, cost, comparative effectiveness, and treatment patterns. This systematic review assessed prevalence and character
Autor:
Monika Raut, Arun Balakumaran, Jinan Liu, Matthew J. Monberg, Xiting Cao, Changxia Shao, Wei Zhou, Alejandro D. Ricart
Publikováno v:
Leukemia & Lymphoma. 60:947-954
Data are limited on the real-world utilization and costs of brentuximab vedotin (BV) among patients with relapsed/refractory Hodgkin lymphoma (rrHL) in the United States. A total of 219 BV patients identified from the Truven MarketScan® databases we
Publikováno v:
Poster.
Objectives Prognosis in ovarian cancer is poor. Previous conditional survival (CS) studies have found outcomes improved based on each year survived since diagnosis. Our objective was to estimate CS and compare to previous studies (≤ 2010). Methods
Publikováno v:
ePoster.
Introduction/Background Despite high response rates to initial treatment, high recurrence rates remain a persistent challenge among patients with ovarian cancer (OC). There is limited data on overall survival (OS) rates and burden of disease with con
Publikováno v:
ePoster.
Introduction/Background This analysis quantifies the burden among ovarian cancer (OC) patients within 4 years of diagnosis who received chemotherapy (chemo) only as 1L treatment. Methodology This chart review and cross-sectional study included advanc
Publikováno v:
ePoster.
Introduction/Background Recent updates to guidelines for the management of ovarian cancer (OC) in Europe and the US include recommendations for BRCA screening and the incorporation of new treatment options. This study sought to quantify regional diff
Publikováno v:
European Journal of Gynaecological Oncology. 42:1252